DrugPatentWatch Database Preview
ADCIRCA Drug Profile
» See Plans and Pricing
Which patents cover Adcirca, and what generic alternatives are available?
Adcirca is a drug marketed by Eli Lilly Co and is included in one NDA.
The generic ingredient in ADCIRCA is tadalafil. There are twenty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
US ANDA Litigation and Generic Entry Outlook for Adcirca
A generic version of ADCIRCA was approved as tadalafil by TEVA PHARMS USA on May 22nd, 2018.
Summary for ADCIRCA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 89 |
Clinical Trials: | 9 |
Patent Applications: | 3,788 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ADCIRCA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ADCIRCA |
DailyMed Link: | ADCIRCA at DailyMed |


Recent Clinical Trials for ADCIRCA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Phase 2 |
Vigonvita Life Sciences | Phase 2 |
Janssen Research & Development, LLC | Phase 1 |
Pharmacology for ADCIRCA
Drug Class | Phosphodiesterase 5 Inhibitor |
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
US Patents and Regulatory Information for ADCIRCA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | AB2 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADCIRCA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | Start Trial | Start Trial |
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ADCIRCA
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 127776 | Start Trial |
Brazil | 9506559 | Start Trial |
Peru | 49495 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ADCIRCA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0740668 | 03C0017 | France | Start Trial | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
0740668 | PA2003001,C0740668 | Lithuania | Start Trial | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
0740668 | PA2003001 | Lithuania | Start Trial | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |